Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice

Bisphosphonates and the anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody denosumab are effective anti-resorptive drugs commonly prescribed for osteoporosis. Both drugs may, however, have intolerable side effects; so, it is critical to examine their residual efficacy such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Omiya, Toshinobu, Hirose, Jun, Omata, Yasunori, Tominari, Tsukasa, Inada, Masaki, Watanabe, Hisato, Miyamoto, Takeshi, Tanaka, Sakae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305378/
https://www.ncbi.nlm.nih.gov/pubmed/32577437
http://dx.doi.org/10.1016/j.bonr.2020.100289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305378/
https://www.ncbi.nlm.nih.gov/pubmed/32577437
http://dx.doi.org/10.1016/j.bonr.2020.100289

Ejemplares similares